The use of the calcineurin inhibitors cyclosporine and tacrolimus led to major advances in
the field of transplantation, with excellent short-term outcome. However, the chronic …

Abstract Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of
transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in …

BACKGROUND: During the past few years, there has been renewed interest in the use of
expanded criteria donors (ECD) for kidney transplantation to increase the numbers of …

Mammalian members of the forkhead box protein O (FoxO) class of transcription factors are
implicated in the regulation of oxidative stress, and FoxO proteins are negatively regulated …

After renal transplantation, hemolytic uremic syndrome (HUS) may occur either as a
recurrent or de novo form. Over the past decade, much effort has been devoted to …

Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal
antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies …

Composite tissue allotransplantations can be indicated when autologous transfers fail to
restore human appearance. We report the reproducibility, difficulties, serious adverse events …

The targeted delivery of therapeutic drugs to lymph nodes (LNs) provides an unprecedented
opportunity to improve the outcomes of transplantation and immune-mediated diseases. The …

Use of the calcineurin inhibitors (CNI) cyclosporine and tacrolimus has revolutionized solid
organ transplantation. For more than 30 yr, the transplant community has dealt with …

The contributions of donor kidney quality (partially determined by donor age), allograft
rejection, and calcineurin inhibitor nephrotoxicity on the progression of histologic damage of …